MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-166 for patients diagnosed with a microorganism infection.
